<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954525</url>
  </required_header>
  <id_info>
    <org_study_id>IND77486</org_study_id>
    <nct_id>NCT00954525</nct_id>
  </id_info>
  <brief_title>Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer</brief_title>
  <official_title>Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible candidates will be adults with metastatic pancreatic cancer (confirmed diagnosis
      with pathology reports and measurable computed tomography (CT) or magnetic resonance imaging
      (MRI)). Participants must not be receiving any other concurrent chemotherapy, or radiation
      therapy. Full inclusion/exclusion criteria are available. History and physical examination,
      and laboratory and imaging analyses will be done within 14 days prior to registration. The
      three cohorts of subjects will receive 50, 75 or 100 grams of intravenous ascorbic acid,
      three times per week for 8 weeks. Subjects will also have co-administration of the
      chemotherapy medications, gemcitabine (intravenously) and erlotinib (orally). Approximately 9
      to 18 participants will be enrolled in this Phase I study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Intravenous Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Erlotinib</intervention_name>
    <description>Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)</description>
    <arm_group_label>Intravenous Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intravenous Vitamin C</intervention_name>
    <description>50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.</description>
    <arm_group_label>Intravenous Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic pancreatic cancer

          -  Glucose 6 phosphate dehydrogenase status normal

          -  ECOG performance status 0-2

          -  Normal creatinine and transaminase

          -  Women of child-bearing potential confirm negative pregnancy test

        Exclusion Criteria:

          -  Concurrent chemotherapy or radiotherapy

          -  Significant co-morbid disorders

          -  Significant psychiatric symptoms

          -  Prior treatment with gemcitabine

          -  Concurrent chronic use of immunosuppressive agents (methotrexate,
             cyclosporine,corticosteroids)

          -  Regular use of nonsteroidal anti-inflammatory agents

          -  Smoking more than 1 pack per day

          -  Excessive alcohol or drug use

          -  Enrollment in other experimental therapy

          -  Active infection

          -  Patients experiencing ongoing response to recent treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jefferson-Myrna Brind Center of Integrative Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Daniel A. Monti, MD</name_title>
    <organization>Thomas Jefferson University</organization>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

